Company Description
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer.
Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients; and Phase I study for various pediatric cancers, r/r head and neck cancers, and R/R MM.
The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors.
It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; Orano Med to develop CLR 12120 Series; IntoCell Inc; and LegoChemBio.
The company was founded in 2002 and is headquartered in Florham Park, New Jersey.
| Country | United States |
| IPO Date | Nov 10, 2005 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 20 |
| CEO | James V. Caruso |
Contact Details
Address: 100 Campus Drive Florham Park, New Jersey United States | |
| Website | https://www.cellectar.com |
Stock Details
| Ticker Symbol | CLRB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001279704 |
| CUSIP Number | 15117F500 |
| ISIN Number | US15117F8077 |
| Employer ID | 04-3321804 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| James V. Caruso | President, Chief Executive Officer & Director |
| Chad J. Kolean CPA | Vice President, Chief Financial Officer & Secretary |
| Jarrod Longcor | Chief Operating Officer |
| Darrell Shane Lea | Chief Commercial Officer |
| Dr. Andrei Shustov M.D. | Senior Vice President of Medical |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 14, 2025 | 8-K | Current Report |
| Dec 11, 2024 | 8-K | Current Report |
| Nov 18, 2024 | 8-K | Current Report |
| Nov 18, 2024 | 10-Q | Quarterly Report |
| Nov 15, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SCHEDULE 13G/A | [Amend] Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 13, 2024 | NT 10-Q | Filing |
| Nov 01, 2024 | 8-K | Current Report |